The cell therapy manufacturing market is estimated to reach close to USD 11 Billion by 2030(RootsAnalysis)
Manufacturing celltherapies is technically and financially demanding; as a result, despitetherapy developers gradually strengthening their in-house expertise, they arealso becoming increasingly reliant on contract service providers
Roots Analysis is pleased toannounce the publication of its recent study, titled, “Cell Therapy Manufacturing Market (3rd Edition),2019 - 2030”.”
The report features an extensive study of thecurrent market landscape and future opportunities associated with cell therapymanufacturing. It focuses on both contract manufacturers, as well as developerswith in-house manufacturing facilities, offering in-depth analyses of thevarious business entities that are engaged in this domain, across differentglobal regions. Amongst other elements, the report includes:
§ An analysis of thevarious expansion initiatives undertaken by service providers, in order toaugment their respective cell therapy manufacturing capabilities, over theperiod 2015-2019.
§ An analysis of therecent partnerships focused on the manufacturing of cell-based therapies, whichhave been established in the period 2014-2019.
§ Informed estimates ofthe annual commercial and clinical demand for cell therapies, in terms ofnumber of cells produced and area dedicated to manufacturing.
§ An estimate of theoverall, installed capacity for manufacturing cell-based therapies based oninformation reported by industry stakeholders in the public domain A competitivenessanalysis of biological targets, featuring insightful pictorial summaries andrepresentations.
§ A detailed analysisof the various factors that are likely to influence the pricing of cell-basedtherapies, featuring different models / approaches that may be adopted bymanufacturers while deciding the prices of their proprietary offerings.
§ A qualitative analysis, highlighting the various factorsthat need to be taken into consideration by cell therapy developers whiledeciding whether to manufacture their respective products in-house or engagethe services of a CMO.
§ An elaborate discussionon the role of automation technologies in improving current manufacturingmethods.
§ A discussion on cell therapy manufacturing regulationsacross various geographies, including North America, Europe, and Asia Pacific.
§ Elaborate profiles ofkey players (industry and non-industry) that offer contract manufacturingservices.
§ A discussion onaffiliated trends, key drivers and challenges, which are likely to impact theindustry’s evolution, under a comprehensive SWOT framework.
§ A detailed marketforecast, featuring analysis of the current and projected future opportunityacross key market segments (listed below)
§ Type of therapy
§ T-cell therapies(CAR-T therapies, TCR therapies, TIL therapies)
§ Dendritic celltherapies
§ Tumor cell therapies
§ NK cell therapies
§ Stem cell therapies
§ Source of cells
§ Autologous
§ Allogeneic
§ Scale of operation
§ Clinical
§ Commercial
§ Purpose ofmanufacturing
§ Contractmanufacturing
§ In-housemanufacturing
§ Key geographicalregions
§ North America
§ Europe
§ Asia Pacific
§ Rest of the world
Keycompanies covered in the report
§ BioNTech InnovativeManufacturing Services
§ Cell Therapies
§ Cell and Gene TherapyCatapult
§ Center for Cell andGene Therapy, Baylor College of Medicine
§ Centre for CellManufacturing Ireland, National University of Ireland
§ Clinical Cell andVaccine Production Facility, University of Pennsylvania
§ Cognate BioServices
§ FUJIFILM
§ Guy’s and St. Thomas’GMP Facility, Guy’s Hospital
§ Hitachi Chemical
§ KBI Biopharma
§ Laboratory for Celland Gene Medicine, Stanford University
§ Lonza
§ MaSTherCell
§ MEDINET
§ Molecular andCellular Therapeutics, University of Minnesota
§ Newcastle CellularTherapies Facility, Newcastle University
§ Nikon CeLL innovation
§ Rayne Cell TherapySuite, King’s College London
§ Roslin Cell Therapies
§ Scottish NationalBlood Transfusion Services Cellular Therapy Facility, Scottish Centre forRegenerative Medicine
§ Sydney Cell and GeneTherapy
§ WuXi AdvancedTherapies
Foradditional details, please visit
https://www.rootsanalysis.com/reports/view_document/cell-therapy-manufacturing/285.htmlor email sales@rootsanalysis.com
Youmay also be interested in the following titles:
1. Celland Advanced Therapies Supply Chain ManagementMarket, 2019-2030
2. RNAiTherapeutics Market (2nd Edition),2019 – 2030
3. GeneTherapy Market (3rd Edition), 2019 –2030
4. StemCell Therapy Contract ManufacturingMarket, 2019-2030
Contact:
GauravChaudhary
+1(415) 800 3415
